|09/07/17||Coherus BioSciences Provides Update on ‘619 IPR Institution Decision|
|Patent Trial and Appeal Board Denies Institution
REDWOOD CITY, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that the Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office denied institution of all four of its petitions for Inter Partes Review (“IPR”) of AbbVie’s U.S. Patent 9,085,619 (“the ‘619 Patent”) related to AbbVie’s HUMIRA (adalimumab) formulation.
“While we are disappointed by this outcome, we c... |
|09/01/17||Coherus BioSciences Management to Present at Three Investor Healthcare Conferences in September|
|REDWOOD CITY, Calif., Sept. 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced that senior management will present at three upcoming investor healthcare conferences.
Management participation in a fireside chat is scheduled at the Wells Fargo Healthcare Conference on Wednesday, September 6th at 8:30 a.m. ET taking place in Boston, MA.
Management participation in a fireside chat is scheduled at the Baird 2017 Global Healthcare Conference on Thursday, S... |
|08/28/17||Coherus BioSciences Announces Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for CHS-1420 (Humira® Biosimilar Candidate) versus European Marketed Humira in Healthy Subjects|
|REDWOOD CITY, Calif., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reported topline results from the first of three ongoing pharmacokinetic bioequivalence (“PK/BE”) studies comparing CHS-1420, a proposed adalimumab (“Humira”) biosimilar candidate versus European marketed Humira. The study met the criteria for clinical PK/BE on all prospectively defined endpoints: maximum serum concentration (Cmax), area under the time-concentration curve from first to last t... |
|08/21/17||Coherus Secures Private Placement from Temasek|
|First tranche of $75 million secured
REDWOOD CITY, Calif., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced plans to raise up to $150 million in a two tranche private placement, the first tranche of $75 million in aggregate gross proceeds to be completed and funded by August 31, 2017 with 6,556,116 shares of common stock to be issued at an offering price of $11.44 per share.
Temasek, an investment company headquartered in Singapore, plans to invest ... |